Siemiątkowska, A.; Bryl, M.; Kosicka-Noworzyń, K.; Tvrdoň, J.; Gołda-Gocka, I.; Barinow-Wojewódzki, A.; Główka, F.K.
Serum sCD25 Protein as a Predictor of Lack of Long-Term Benefits from Immunotherapy in Non-Small Cell Lung Cancer: A Pilot Study. Cancers 2021, 13, 3702.
https://doi.org/10.3390/cancers13153702
AMA Style
Siemiątkowska A, Bryl M, Kosicka-Noworzyń K, Tvrdoň J, Gołda-Gocka I, Barinow-Wojewódzki A, Główka FK.
Serum sCD25 Protein as a Predictor of Lack of Long-Term Benefits from Immunotherapy in Non-Small Cell Lung Cancer: A Pilot Study. Cancers. 2021; 13(15):3702.
https://doi.org/10.3390/cancers13153702
Chicago/Turabian Style
Siemiątkowska, Anna, Maciej Bryl, Katarzyna Kosicka-Noworzyń, Jakub Tvrdoň, Iwona Gołda-Gocka, Aleksander Barinow-Wojewódzki, and Franciszek K. Główka.
2021. "Serum sCD25 Protein as a Predictor of Lack of Long-Term Benefits from Immunotherapy in Non-Small Cell Lung Cancer: A Pilot Study" Cancers 13, no. 15: 3702.
https://doi.org/10.3390/cancers13153702
APA Style
Siemiątkowska, A., Bryl, M., Kosicka-Noworzyń, K., Tvrdoň, J., Gołda-Gocka, I., Barinow-Wojewódzki, A., & Główka, F. K.
(2021). Serum sCD25 Protein as a Predictor of Lack of Long-Term Benefits from Immunotherapy in Non-Small Cell Lung Cancer: A Pilot Study. Cancers, 13(15), 3702.
https://doi.org/10.3390/cancers13153702